Blissenbach Board Certified Excellence Dr
Semaglutide and walking capacity in symptomatic PAD and type 2 diabetes patients: the STRIDE trial Selected in The Lancet by Xavier Devoisin This phase 3b, double-blind, randomised, placebo-controlled trial assessed the effect of semaglutide on walking capacity in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes
The team leads with information, science, and a clear health use case
Important Discontinuation Instructions In order to avoid developing withdrawal symptoms, instruct patients not to discontinue oxycodone and acetaminophen tablets without first discussing a tapering plan with the prescriber [see DOSAGE AND ADMINISTRATION]
TRIUMPH-1, -2, and -3 run for 80 weeks (16 weeks escalation + 64 weeks maintenance)
Swallow with a glass of water or a cold drink